Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...

Fintel reports that on March 17, 2025, William Blair upgraded their outlook for DocuSign (NasdaqGS:DOCU) from Market Perform ...

Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.

Butterfly Network exceeded Q4 estimates with 35% revenue growth. William Blair sees strong upside, citing homecare potential ...

We recently published a list of 11 Best Reddit Stocks to Invest In. In this article, we are going to take a look at where ...

Software company DocuSign (DOCU) scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism about ...

A Wall Street analyst believes Palantir's (NASDAQ: PLTR) expanding artificial intelligence (AI) ecosystem, marked by major ...

William Blair analyst Louie DiPalma maintained a Hold rating on Science Applications (SAIC – Research Report) today. The company’s shares ...